Angiogenesis Inhibitors

"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.

Descriptor ID	D020533
MeSH Number(s)	D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
Concept/Terms	Angiogenesis Inhibitors Angiogenesis Inhibitors Neovascularization Inhibitors Angiogenic Antagonists Angiogenic Inhibitors Angiostatic Agents Agents, Angiostatic Antagonists, Angiogenic Anti-Angiogenetic Agents Agents, Anti-Angiogenetic Anti Angiogenetic Agents Anti-Angiogenic Drugs Anti Angiogenic Drugs Drugs, Anti-Angiogenic Antiangiogenic Agents Agents, Antiangiogenic Inhibitors, Angiogenesis Inhibitors, Angiogenetic Inhibitors, Angiogenic Inhibitors, Neovascularization Angiogenetic Antagonists Antagonists, Angiogenetic Angiogenetic Inhibitors Angiogenesis Factor Inhibitors Angiogenesis Factor Inhibitors Factor Inhibitors, Angiogenesis Inhibitors, Angiogenesis Factor Anti-Angiogenesis Effect Anti-Angiogenesis Effect Anti Angiogenesis Effect Effect, Anti-Angiogenesis Antiangiogenesis Effect Effect, Antiangiogenesis Antiangiogenesis Effects Effects, Antiangiogenesis Anti-Angiogenesis Effects Anti Angiogenesis Effects Effects, Anti-Angiogenesis

Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Growth Substances [D27.505.696.377]
Angiogenesis Modulating Agents [D27.505.696.377.077]
Angiogenesis Inhibitors [D27.505.696.377.077.099]
Growth Inhibitors [D27.505.696.377.450]
Angiogenesis Inhibitors [D27.505.696.377.450.100]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Angiogenesis Inhibitors [D27.505.954.248.025]

Below are MeSH descriptors whose meaning is related to "Angiogenesis Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.

Bar chart showing 63 publications over 18 distinct years, with a maximum of 7 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2002	1	0	1
2003	3	0	3
2005	3	0	3
2007	3	1	4
2008	3	1	4
2009	1	0	1
2010	3	3	6
2011	3	0	3
2012	4	0	4
2013	4	1	5
2014	4	1	5
2015	6	1	7
2016	1	1	2
2017	2	3	5
2018	2	2	4
2019	1	2	3
2020	0	2	2

Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.

duPont NC, Enserro D, Brady MF, Moxley K, Walker JL, Cosgrove C, Bixel K, Tewari KS, Thaker P, Wahner Hendrickson AE, Rubin S, Fujiwara K, Casey AC, Soper J, Burger RA, Monk BJ. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2022 02; 164(2):398-405.

View in: PubMed
Lin PK, Salvador J, Xie J, Aguera KN, Koller GM, Kemp SS, Griffin CT, Davis GE. Selective and Marked Blockade of Endothelial Sprouting Behavior Using Paclitaxel and Related Pharmacologic Agents. Am J Pathol. 2021 12; 191(12):2245-2264.

View in: PubMed
Sassine J, Kontoyiannis DP. A 77-Year-Old Man with Multiple Myeloma and a Lytic Bone Lesion. Am J Med. 2021 07; 134(7):860-862.

View in: PubMed
Schafer CM, Gurley JM, Kurylowicz K, Lin PK, Chen W, Elliott MH, Davis GE, Bhatti F, Griffin CT. An inhibitor of endothelial ETS transcription factors promotes physiologic and therapeutic vessel regression. Proc Natl Acad Sci U S A. 2020 10 20; 117(42):26494-26502.

View in: PubMed
Wallace DK, Kraker RT, Freedman SF, Crouch ER, Bhatt AR, Hartnett ME, Yang MB, Rogers DL, Hutchinson AK, VanderVeen DK, Haider KM, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Kong L, Cotter SA, Holmes JM. Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol. 2020 06 01; 138(6):698-701.

View in: PubMed
Wade KNS, Brady MF, Thai T, Wang Y, Zheng B, Salani R, Tewari KS, Gray HJ, Bakkum-Gamez JN, Burger RA, Moore KN, Bookman MA. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. Gynecol Oncol. 2019 10; 155(1):69-74.

View in: PubMed
Invernizzi A, Nguyen V, Teo K, Barthelmes D, Fung A, Vincent A, Gillies M. Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project. Am J Ophthalmol. 2019 08; 204:105-112.

View in: PubMed
Gillen J, Richardson D, Moore K. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 02 26; 21(3):22.

View in: PubMed
Palavalli Parsons LH, Roane B, Manders DB, Richardson DL, Kehoe SM, Carlson M, Miller DS, Lea JS. Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer. Am J Clin Oncol. 2018 10; 41(10):933-937.

View in: PubMed
Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252.

View in: PubMed

People

Explore

Similar Concepts

Top Journals